Reference entry · Acylated GLP-1 receptor agonist
Semaglutide
Also known as: GLP-1 receptor agonist · Ozempic/Wegovy (approved drug names)
- Class
- Acylated GLP-1 receptor agonist
- Primary targets (literature)
- GLP-1 receptor
- Regulatory context
- FDA-approved drug (branded products exist). Catalog semaglutide for laboratory use is not those approved products unless explicitly sourced and documented as such.
Overview
Semaglutide is a GLP-1 receptor agonist with extensive published human trial literature as an approved drug product. Catalog research peptide labeled semaglutide is a separate RUO material — not interchangeable with pharmaceutical formulations without verified identity and context.
Mechanism in research literature
GLP-1 receptor activation influences insulin secretion, glucagon suppression, gastric emptying, and central satiety pathways in research and clinical models.
Common research focus areas
- Phase 3 cardiovascular and metabolic outcomes
- Acylation and half-life pharmacology
- Catalog vs. pharmaceutical material distinction
- Mass-spec confirmation of intact acylated structure
Full literature roundup
Read the cited research summary
A GLP-1 receptor agonist with extensive published literature. What preclinical and clinical research reports — within an RUO frame.
Semaglutide research roundup · 5 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.